兆科眼科(06622.HK)與國藥控股(01099.HK)等達成戰略合作
兆科眼科(06622.HK)宣佈,與國藥控股(01099.HK)旗下國藥控股分銷中心、上藥控股及華潤醫藥商業集團先後簽訂戰略合作協議,展開採購模式、物流管理、市場開發、合作項目及信息溝通等多方面合作。
公司將向合作方提供自行生產的符合國家品質標準的醫藥產品,實現整體業務合作。雙方並加強溝通物流合作資訊及經驗,積極拓展協力廠商物流和多倉運行合作模式,提高物流配送效率。
公司預期,藉助合作方的銷售網路可提升旗下產品的終端覆蓋,開發零售管道及管道增值業務,提高患者藥品可及性。未來合作方將在產品經銷以及與經銷直接相關領域合作拓展,並在線上管道領域進行全方位合作,探討「醫療健康+互聯網」領域合作。
兆科眼科董事局主席、執行董事兼行政總裁李小羿表示,與三家中國領先的醫藥供應鏈服務企業的合作,爲公司即將實現產品商業化提供高效、強大的銷售網路,意味兆科眼科從一家研發階段的公司,正式向商業化邁進。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.